AGP Executive Report
Last update: 3 hours agoEU Health Breakthrough: The European Commission granted marketing authorisation for NEZGLYAL® (leriglitazone) under exceptional circumstances for male childhood cerebral adrenoleukodystrophy (cALD), the first pharmacological early-intervention option in the EU; Local Pharma Watch: Neuren’s Rett syndrome drug approval is already translating into plans for first European commercial sales, with a milestone payment tied to first sales; Digital Identity & Travel Tech: The .eu domain celebrates 20 years as everyday European internet infrastructure, while Europe’s EES border system keeps reshaping travel with biometric checks across Schengen countries including Liechtenstein; Fintech & Crypto: BTCNow launches a pay-over-time model for Bitcoin ownership with fixed pricing and custody via BitGo, aiming to avoid margin calls; Onchain Finance: Ondo rolled out tokenised portfolio exposure via single onchain tokens, using BlackRock “Powered by” strategies; Trade & Investment: India’s EFTA TEPA hits its one-year mark, with USD 100bn investment and job targets, and Switzerland’s president is set to visit for trade talks; US Pharma Tariffs: The US clarified Section 232 specialty-drug exemptions, with India among eligible jurisdictions for 0% tariff treatment on select categories.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
